Skip to main content
. 2022 Jan 24;22:100. doi: 10.1186/s12885-022-09197-w

Fig. 2.

Fig. 2

Percentage confluence 7-days after treatment with azacitidine, carboplatin or combination azacitidine and carboplatin in (A) all cell lines, (B) BRCA-wildtype cell lines, and (C) BRCA-mutant cell lines. Data displayed is mean ± SEM of triplicates of three independent experiments